Menopause Monitoring Schedule: Exact Tests, Timing, and Follow-Up Intervals

How Menopause Is Diagnosed

Menopause is a clinical diagnosis. A woman aged 45 or older who has gone 12 consecutive months without a menstrual period meets the standard definition established by the World Health Organization and reaffirmed by the North American Menopause Society (NAMS). No single blood test is required to confirm the diagnosis in this age group.

Lab testing becomes useful in specific scenarios. Women younger than 45 with suspected premature ovarian insufficiency (POI) need two serum FSH measurements drawn 4 to 6 weeks apart, each above 25 mIU/mL, to confirm the diagnosis per Endocrine Society 2015 guidelines. Women on hormonal contraception or with a prior hysterectomy also present diagnostic challenges where FSH and estradiol levels add clarity.

A baseline TSH should be drawn at the same time. Hypothyroidism affects roughly 5% of women over 50 and can mimic vasomotor symptoms, fatigue, and mood changes [1]. Ruling it out prevents misattribution of symptoms. A serum estradiol below 20 pg/mL, combined with FSH above 30 mIU/mL, strengthens diagnostic confidence when the clinical timeline is unclear.

The 2022 NAMS position statement specifies that anti-Mullerian hormone (AMH) testing is not recommended for routine menopause diagnosis [2]. AMH may predict time to final menstrual period in research settings, but it has no validated clinical cutoff for confirming menopause.

Baseline Labs Before Starting Hormone Therapy

Before initiating any menopause treatment, a complete baseline lab panel establishes metabolic and hormonal reference points. The Endocrine Society and NAMS both recommend this workup prior to prescribing estrogen, progesterone, or combination HRT [3].

The baseline panel should include:

• FSH and estradiol (if diagnosis is uncertain)
• TSH (to exclude thyroid disease)
• Complete metabolic panel (liver function, kidney function, fasting glucose)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• CBC (complete blood count)
• Mammogram (within the past 12 months)

Liver function testing matters because oral estrogen undergoes first-pass hepatic metabolism. Women with elevated transaminases or active liver disease may need transdermal estradiol instead, which bypasses the liver [4]. The Endocrine Society's 2015 clinical practice guideline on HRT management specifies hepatic function screening before oral estrogen initiation.

Fasting triglycerides deserve special attention. Oral estrogen can raise triglycerides by 25% to 50%, a significant concern for women with baseline levels above 200 mg/dL [5]. Transdermal estradiol has a neutral or mildly beneficial effect on triglycerides, making it the preferred route in hypertriglyceridemia. The 2020 AACE lipid guidelines recommend reassessing triglycerides 6 to 12 weeks after starting oral estrogen if the patient's baseline exceeded 150 mg/dL.

Blood pressure measurement at baseline is non-negotiable. The Women's Health Initiative (WHI) showed a small but statistically significant rise in systolic blood pressure (1.5 mmHg mean increase) among women on conjugated equine estrogen plus medroxyprogesterone acetate over 5.6 years of follow-up [6].

The 3-Month Follow-Up Visit

The first follow-up after starting HRT should occur at approximately 12 weeks. This visit prioritizes symptom assessment over lab work. The clinician evaluates hot flash frequency and severity, sleep quality, mood stability, and vaginal symptoms using a validated tool like the Menopause Rating Scale (MRS) or the Greene Climacteric Scale.

At 3 months, most women on standard-dose estradiol (1 mg oral or 0.05 mg/day transdermal patch) will report a 60% to 80% reduction in vasomotor symptom frequency. The KEEPS trial (N=727) showed that both oral conjugated equine estrogen 0.45 mg/day and transdermal estradiol 0.05 mg/day significantly reduced hot flash frequency by week 12 compared to placebo [7].

Side effects to screen for at this visit include breast tenderness, bloating, headache, and unscheduled bleeding. Unscheduled bleeding in the first 3 months of combined continuous HRT is common (occurring in up to 40% of women) and typically resolves by month 6 [8]. If it persists or is heavy, transvaginal ultrasound is indicated.

No routine blood work is mandatory at 3 months for most patients. Exceptions: women started on oral estrogen with borderline triglycerides (150 to 199 mg/dL) should have a repeat fasting lipid panel. Women on thyroid replacement whose estrogen dose changed should have TSH rechecked, because oral estrogen increases thyroxine-binding globulin and may require a levothyroxine dose adjustment.

The 6-Month Follow-Up and Lab Reassessment

At 6 months, clinical reassessment is paired with targeted lab work. This is the visit where dose optimization happens. If vasomotor symptoms have not adequately improved, the clinician may increase estradiol dose (e.g., from 0.5 mg to 1 mg oral, or from a 0.0375 mg to 0.05 mg patch).

Labs to order at 6 months:

• Fasting lipid panel (assess estrogen's effect on LDL, HDL, triglycerides)
• Fasting glucose or HbA1c (if metabolic risk factors present)
• Serum estradiol (optional, useful if symptoms are not improving despite adequate doses)

Checking serum estradiol at this point helps distinguish between inadequate absorption and inadequate dosing. Target serum estradiol for symptom control generally falls between 40 and 100 pg/mL, though this is a clinical guide rather than a rigid cutoff. A woman on 0.05 mg/day transdermal estradiol whose serum level is 25 pg/mL may simply need a higher patch dose.

The 6-month visit is also the time to assess bleeding patterns in women on combined HRT. Per the 2017 NAMS position statement, any bleeding that persists beyond 6 months of continuous combined HRT warrants endometrial evaluation, typically starting with transvaginal ultrasound [2]. An endometrial thickness of 4 mm or less is reassuring. Thickness above 4 mm, or persistent bleeding with a thin stripe, requires endometrial biopsy.

Annual Monitoring: The Recurring Yearly Protocol

After the first year, menopause monitoring settles into an annual cycle. Each yearly visit should cover five domains: symptom status, cardiovascular risk, metabolic health, bone health screening, and cancer surveillance.

Symptom reassessment. Use the same validated scale from previous visits for comparability. The 2022 NAMS position statement recommends annual review of whether HRT benefits still outweigh risks for the individual patient [2]. This is not a mandate to discontinue therapy at any fixed duration. The statement explicitly rejects arbitrary time limits on HRT use.

Cardiovascular markers. Fasting lipid panel and blood pressure measurement annually. The WHI observational data showed that women who initiated HRT within 10 years of menopause had a lower coronary heart disease risk (HR 0.76, 95% CI 0.50 to 1.16), while those starting more than 20 years post-menopause had elevated risk (HR 1.28, 95% CI 0.84 to 1.97) [6]. This "timing hypothesis," confirmed in the 2016 ELITE trial (N=643), reinforces that cardiovascular monitoring intensity should match the patient's time since menopause onset [9].

Metabolic screening. Fasting glucose or HbA1c annually. Menopause independently increases insulin resistance. The SWAN study (N=1,237 women followed across the menopause transition) documented a 60% increase in metabolic syndrome prevalence within 4 years of the final menstrual period [10].

Cancer surveillance. Mammography per USPSTF guidelines: biennially for women aged 50 to 74, or annually if on combined estrogen-progestogen HRT based on shared decision-making [11]. The WHI found that combined HRT increased breast cancer risk with a hazard ratio of 1.26 (95% CI 1.00 to 1.59) over a mean 5.6 years of use, while estrogen-alone therapy in women with prior hysterectomy actually showed a non-significant reduction (HR 0.77, 95% CI 0.59 to 1.01) [6].

Bone Density Screening and Osteoporosis Prevention

The USPSTF recommends DEXA screening for all women at age 65 [11]. Earlier screening, beginning at menopause onset, applies to women with one or more risk factors: low body weight (BMI <20), prior fracture, glucocorticoid use exceeding 3 months, family history of hip fracture, smoking, or excessive alcohol intake.

DEXA results guide monitoring intervals. A T-score at or above -1.0 (normal) typically warrants rescreening in 10 to 15 years. T-scores between -1.0 and -1.5 (mild osteopenia) can be rescreened in 5 years. T-scores between -1.5 and -2.0 warrant rescreening in 3 years. T-scores at or below -2.5 (osteoporosis) require treatment initiation and follow-up DEXA in 2 years to assess response [12].

The Study of Osteoporotic Fractures (SOF) data showed that postmenopausal women lose roughly 1% to 2% of bone mineral density per year in the first 5 to 7 years after menopause, then the rate slows [13]. HRT is the most effective pharmacologic intervention for preventing this early rapid loss. The WHI demonstrated a 34% reduction in hip fractures (HR 0.66, 95% CI 0.45 to 0.98) and a 24% reduction in total fractures among women on combined HRT [6].

Vitamin D and calcium status should be checked at baseline and corrected before interpreting DEXA trends. The Endocrine Society recommends a 25-hydroxyvitamin D level of at least 30 ng/mL for optimal bone health, with supplementation of 1,500 to 2,000 IU/day for deficient patients [14]. Calcium intake should target 1,200 mg/day from diet and supplements combined for postmenopausal women, per the National Osteoporosis Foundation guidelines.

Monitoring Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause (GSM) affects up to 84% of postmenopausal women, according to a 2019 systematic review (N=8,382 across 16 studies), yet remains underdiagnosed because many women do not volunteer these symptoms [15]. GSM includes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs.

Screening should occur at every annual visit. A direct question works best. The NAMS 2020 GSM position statement recommends asking: "Do you have vaginal dryness, pain with intercourse, or urinary symptoms?" [16]. Validated instruments like the Vulvovaginal Symptom Questionnaire (VSQ) can quantify severity for tracking over time.

For women on systemic HRT who still report GSM symptoms, low-dose vaginal estrogen (10 mcg estradiol vaginal tablet or 0.5 mg estradiol vaginal ring) can be added. The Cochrane review by Lethaby et al. (2016) found that local vaginal estrogen was significantly more effective than placebo for all GSM symptoms, with no increase in endometrial hyperplasia at low doses [17].

Vaginal pH testing (normal postmenopausal pH is 5.0 to 7.0, compared to premenopausal 3.5 to 4.5) and the vaginal maturation index can objectively track GSM treatment response, though these are used more in research than routine practice.

Cardiovascular Risk: Lipids, Glucose, and Blood Pressure Timeline

Cardiovascular disease is the leading cause of death in postmenopausal women. The loss of endogenous estrogen accelerates atherosclerosis, and the menopausal transition itself is associated with unfavorable shifts in the lipid profile. The SWAN Heart Study documented mean LDL increases of 10 to 15 mg/dL across the menopause transition, independent of aging [18].

The monitoring timeline for cardiovascular markers:

• Baseline: Fasting lipids, fasting glucose, HbA1c, blood pressure
• 3 months: Blood pressure recheck (particularly if starting oral estrogen)
• 6 months: Fasting lipids (especially triglycerides on oral estrogen)
• Annually thereafter: Full fasting lipids, fasting glucose or HbA1c, blood pressure

The 2019 ACC/AHA cardiovascular risk guidelines recommend using the 10-year ASCVD risk calculator at age 40, then reassessing every 4 to 6 years. Menopause-specific risk enhancers recognized by the ACC include premature menopause (before age 40), which carries a relative risk of 1.5 for cardiovascular events [19].

Dr. JoAnn Manson, principal investigator of the WHI, stated in her 2020 JAMA review: "The preponderance of evidence supports a 'window of opportunity' for initiating hormone therapy, with the most favorable benefit-risk profile when therapy is started within 10 years of menopause onset or before age 60" [20].

When to Refer: Red Flags During Monitoring

Not all findings during routine monitoring can be managed in primary care. Specific results require subspecialty referral on an expedited timeline.

Refer to gynecology or gynecologic oncology if endometrial thickness exceeds 4 mm on transvaginal ultrasound with persistent postmenopausal bleeding, or if endometrial biopsy shows hyperplasia with atypia. The ACOG Practice Bulletin No. 149 (reaffirmed 2020) specifies that complex atypical hyperplasia carries a concurrent endometrial cancer rate of up to 43% [21].

Refer to endocrinology if a woman under 40 meets criteria for premature ovarian insufficiency. POI requires workup for autoimmune adrenal insufficiency (21-hydroxylase antibodies), karyotype analysis to rule out Turner syndrome mosaicism, and FMR1 premutation screening [3].

Refer to cardiology if the 10-year ASCVD risk exceeds 7.5%, particularly in women with premature menopause as a risk enhancer. The USPSTF recommends statin consideration at this threshold, and the decision requires shared decision-making with a cardiovascular specialist when HRT is concurrent [19].

Refer to rheumatology or endocrinology if DEXA T-score is at or below -2.5 with a fragility fracture. The American Association of Clinical Endocrinologists 2020 guideline classifies this as "very high fracture risk" requiring anabolic therapy (teriparatide or romosozumab) before antiresorptive sequencing [22].

Dr. Stephanie Faubion, NAMS Medical Director, noted in the society's 2022 hormone therapy position statement: "Annual assessment should include a review of new data and each patient's changing risk profile. The decision to continue, modify, or discontinue hormone therapy should be individualized" [2].

Monitoring After Discontinuing HRT

Stopping HRT requires its own follow-up protocol. Vasomotor symptoms recur in roughly 50% of women after discontinuation, according to a 2014 JAMA Internal Medicine analysis of WHI participants [23]. Gradual tapering over 3 to 6 months (reducing dose by 50% every 4 to 8 weeks) produces fewer rebound symptoms than abrupt cessation.

After HRT discontinuation, the monitoring schedule should include:

• Month 1 to 3: Symptom reassessment for vasomotor recurrence
• Month 6: Fasting lipids (LDL may rise 10 to 15% after estrogen withdrawal)
• Year 1: DEXA if the patient was relying on HRT for bone protection and has osteopenia or risk factors
• Annually: Standard postmenopausal cardiovascular and metabolic screening

Bone loss accelerates after HRT cessation. The WHI post-stopping analysis showed that the fracture protection conferred by HRT was lost within 2 to 3 years of discontinuation [24]. Women with T-scores in the osteopenic range at the time of HRT cessation should be considered for bisphosphonate or denosumab transition to preserve bone density gains.

The breast cancer risk associated with combined HRT decreases after stopping therapy, returning to baseline within approximately 5 years, per the Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis (2019) pooling data from 108,647 women [25]. This timeline should inform mammography discussions during post-HRT follow-up.